| |
ILC (n = 131)
|
IDC (n = 133)
|
Total cases (n = 264)
|
P-value
|
|---|
|
Age (years)
|
59 (35–87)
|
55 (24–82)
|
57 (24–87)
|
0.001
|
|
Tumor size (cm)
|
2.0 (0.2–9.0)
|
1.5 (0.1–6.5)
|
1.7 (0.1–9.0)
|
0.006
|
|
T-stage
| | | | |
|
T1
|
75(58%)
|
88 (66%)
|
163 (62%)
|
0.298
|
|
T2
|
49 (38%)
|
43 (32%)
|
92 (35%)
| |
|
T3
|
5 (4%)
|
2 (2%)
|
7 (3%)
| |
|
T4
|
1 (1%)
|
0 (0%)
|
1 (0.5%)
| |
|
Tumor focality
| | | | |
|
Unifocal
|
97 (75%)
|
123 (93%)
|
220 (84%)
|
<0.001
|
|
Multifocal
|
19 (15%)
|
9 (7%)
|
28 (11%)
| |
|
Multicentric
|
14 (11%)
|
1 (1%)
|
15 (6%)
| |
|
Histologic grade
| | | | |
|
Grade 1
|
40 (31%)
|
32 (24%)
|
72 (27%)
|
<0.001
|
|
Grade 2
|
57 (44%)
|
52 (39%)
|
109 (41%)
| |
|
Grade 3
|
17 (13%)
|
48 (36%)
|
65 (25%)
| |
|
Unknown
|
17 (13%)
|
1 (1%)
|
18 (7%)
| |
|
ER status
| | | | |
|
Positive
|
121 (93%)
|
96 (72%)
|
217 (82)
|
<0.001
|
|
Negative
|
2 (2%)
|
29 (22%)
|
31 (12%)
| |
|
Unknown
|
8 (6%)
|
8 (6%)
|
16 (6%)
| |
|
PR status
| | | | |
|
Positive
|
108 (82%)
|
81 (61%)
|
189 (72%)
|
<0.001
|
|
Negative
|
16 (12%)
|
44 (33%)
|
60 (23%)
| |
|
Unknown
|
7 (5%)
|
8 (6%)
|
15 (6%)
| |
|
Her-2/neu
| | | | |
|
Positive
|
13 (10%)
|
35 (26%)
|
48 (18%)
|
0.003
|
|
Negative
|
106 (81%)
|
87 (65%)
|
193 (73%)
| |
|
Unknown
|
12 (9%)
|
11 (8%)
|
23 (9%)
| |
|
LVI
| | | | |
|
Positive
|
20 (15%)
|
41 (31%)
|
61 (23%)
|
0.005
|
|
Negative
|
109 (83%)
|
92 (69%)
|
201 (76%)
| |
|
Unknown
|
2 (2%)
|
0 (0%)
|
2 (1%)
| |
- ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma; ER, estrogen receptor; PR, progesterone receptor; LVI, lymphovascular invasion
